583031-22-5

Upstream product

• 104097-04-3 1-(diethoxyphosphorylmethyl)-3-nitro-benzene 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1211579-47-3 4-(4-nitrobenzylidene)piperidine 
• 3958-57-4 1-bromomethyl-3-nitrobenzene 

Downstream Products

• 586412-80-8 4-(3-nitrobenzylidene)piperidine hydrochloride 
• 1299488-89-3 1-(cyclopropylmethyl)-3-(3-((1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)piperidin-4-yl)methyl)phenyl)urea 
• 676528-03-3 tert-butyl 4-(3-aminobenzyl)piperidine-1-carboxylate 
• 1299488-90-6 2-(4-((4-(3-aminobenzyl)piperidin-1-yl)methyl)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol 
• 773848-28-5 3-(piperidin-4-ylmethyl)aniline 

Relevant academic research and scientific papers

MACROCYLIC PYRIMIDINE DERIVATIVES

The present invention relates to substituted macrocylic pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.

(1,1, 1,3, 3, 3-HEXAFLUORO-2-HYDROXYPROPAN-2-YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR USE FOR THE TREATMENT OF ATHEROSCLEROSIS

The present invention relates to (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl derivatives having the general formula (I) to pharmaceutical compositions comprising the same and to the use of these (1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl

Discovery of potent, orally bioavailable, selective 5-HT1A/B/D receptor antagonists

5-HT1 receptor antagonists have been discovered with good selectivity over the 5-HT transporter. This is the first report of highly potent, selective ligands for the 5-HT1A/B/D receptors with low intrinsic activity, which represent a